BioReperia

With our unique ZTX platform (zebrafish tumor xenograft), its possible to accelerate drug discovery and determine the best drug available for each patient within a few days. BioReperia is a Swedish contract research organization (CRO) developing new products to accelerate drug discovery, improve the diagnosis of cancer patients, and increase the success rate in clinical trials using zebrafish models. Our proprietary platform reduces the prediction time for the right anti-cancer treatment in individual cancer patients from 6 months to 5 days. It also allows metastasis invasion within 3 days, providing in vivo data on tumor regression and metastasis inhibition of...

Oncology,drug discovery,toxicology,zebrafish,clinical trials,pdx models,precision medicine,drug development,cdx models,immunotherapy,patient stratification,lead optimization,target validation,and screening

Bioreperia operates in the Biotechnology research industry.

Bioreperia's revenue is 11m - 100m

Bioreperia has 11 - 50 employees.